Gujarat Themis Biosyn Limited

Equities

GUJTHEM6

INE942C01045

Pharmaceuticals

Market Closed - Bombay S.E. 06:19:44 2024-05-10 am EDT 5-day change 1st Jan Change
398.5 INR +0.61% Intraday chart for Gujarat Themis Biosyn Limited -2.08% +55.33%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Gujarat Themis Biosyn Limited Approves an Interim Dividend for the Year 2023-24 CI
Gujarat Themis Biosyn Limited Approves Interim Dividend for the Financial Year 2023-24 CI
Gujarat Themis Biosyn Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Gujarat Themis Biosyn Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Gujarat Themis Biosyn Limited Recommends Dividend for Financial Year Ended March 31, 2023 CI
Gujarat Themis Biosyn Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023 CI
Gujarat Themis Biosyn Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Gujarat Themis Biosyn Names New CEO MT
Gujarat Themis Biosyn Limited Appoints Tapas Guha Thakurata as Chief Executive Officer CI
Gujarat Themis Biosyn Board Declares Interim Dividend for Fiscal 2023 MT
Gujarat Themis Biosyn Limited Approves Declaration of an Interim Dividend for the Financial Year 2022-23 CI
Gulf Oil Lubricants' Net Profit Slides in Fiscal Q2 MT
Gujarat Themis Biosyn's Net Profit Climbs in Fiscal Q2 MT
Gujarat Themis Biosyn Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Themis Medicare Limited entered into share purchase agreement to acquire additional 6.47% stake in Gujarat Themis Biosyn Limited from Pharmaceutical Business Group Limited for approximately INR 700 million. CI
Gujarat Themis Biosyn Limited Recommends Dividend for the Financial Year 2021-22 CI
CARE Upgrades Rating on Gujarat Themis Biosyn's Long-term Bank Financing; Outlook Stable MT
Gujarat Themis Biosyn Limited Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
Gujarat Themis Biosyn CEO Steps Down MT
Gujarat Themis Biosyn Limited Announces Resignation of Mr. Jagadish O. Kauiaigi, Chief Executive Officer CI
Gujarat Themis Biosyn CEO Steps Down MT
Gujarat Themis Biosyn Limited Announces Resignation of Jagadish G. Kaujalgi, Chief Executive Officer, Effective 10 July 2022 CI
Gujarat Themis Biosyn Limited Recommends Dividend for Financial Year Ended March 31, 2022 CI
Gujarat Themis Biosyn Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021 CI
Gujarat Themis Biosyn Limited Declares an Interim Dividend for the Financial Year 2021-2022 CI
Chart Gujarat Themis Biosyn Limited
More charts
Gujarat Themis Biosyn Limited is an India-based company, which is principally engaged in the manufacturing of pharmaceuticals and medicinal chemical products. The Company is focused on the business of manufacturing and sale of finished active pharmaceutical ingredients (API) products by fermentation process. The Company operates through manufacturing of the bulk drugs segment. Its product portfolio comprises Rifamycin-O and Rifamycin-S. The Company is manufacturing Rifamycin S, which is an intermediate for manufacturing the drug Rifampicin (an Antibiotic used for the treatment of several types of bacterial infections, including tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease.) and Rifamycin O, which is an intermediate for manufacturing the drug Rifaximin (this is an Antibiotic used for treatment of traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy). Its research and development division focuses on developing fermentation cultures.
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW